Cargando…
Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve?
Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs)...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312256/ https://www.ncbi.nlm.nih.gov/pubmed/22481968 http://dx.doi.org/10.1155/2012/397648 |
_version_ | 1782227831503192064 |
---|---|
author | Nguyen-Pham, Thanh-Nhan Lee, Yoon-Kyung Kim, Hyeoung-Joon Lee, Je-Jung |
author_facet | Nguyen-Pham, Thanh-Nhan Lee, Yoon-Kyung Kim, Hyeoung-Joon Lee, Je-Jung |
author_sort | Nguyen-Pham, Thanh-Nhan |
collection | PubMed |
description | Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF, which are produced from myeloma cells, can modulate antitumor host immune response, including the abrogation of DC function, by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the efficacy of DC vaccination in MM. |
format | Online Article Text |
id | pubmed-3312256 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33122562012-04-05 Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? Nguyen-Pham, Thanh-Nhan Lee, Yoon-Kyung Kim, Hyeoung-Joon Lee, Je-Jung Clin Dev Immunol Review Article Multiple myeloma (MM) is a good target disease in which one can apply cellular immunotherapy, which is based on the graft-versus-myeloma effect. This role of immune effector cells provides the framework for the development of immune-based therapeutic options that use antigen-presenting cells (APCs) with increased potency, such as dendritic cells (DCs), in MM. Current isolated idiotype (Id), myeloma cell lysates, myeloma dying cells, DC-myeloma hybrids, or DC transfected with tumor-derived RNA has been used for immunotherapy with DCs. Immunological inhibitory cytokines, such as TGF-β, IL-10, IL-6 and VEGF, which are produced from myeloma cells, can modulate antitumor host immune response, including the abrogation of DC function, by constitutive activation of STAT3. Therefore, even the immune responses have been observed in clinical trials, the clinical response was rarely improved following DC vaccinations in MM patients. We are going to discuss how to improve the efficacy of DC vaccination in MM. Hindawi Publishing Corporation 2012 2012-03-15 /pmc/articles/PMC3312256/ /pubmed/22481968 http://dx.doi.org/10.1155/2012/397648 Text en Copyright © 2012 Thanh-Nhan Nguyen-Pham et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Nguyen-Pham, Thanh-Nhan Lee, Yoon-Kyung Kim, Hyeoung-Joon Lee, Je-Jung Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
title | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
title_full | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
title_fullStr | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
title_full_unstemmed | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
title_short | Immunotherapy Using Dendritic Cells against Multiple Myeloma: How to Improve? |
title_sort | immunotherapy using dendritic cells against multiple myeloma: how to improve? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312256/ https://www.ncbi.nlm.nih.gov/pubmed/22481968 http://dx.doi.org/10.1155/2012/397648 |
work_keys_str_mv | AT nguyenphamthanhnhan immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove AT leeyoonkyung immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove AT kimhyeoungjoon immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove AT leejejung immunotherapyusingdendriticcellsagainstmultiplemyelomahowtoimprove |